A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC.
- DOI
- 10.1016/j.isci.2026.117995
- Published
- 2026 Nov 20
- Container
- iScience
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.isci.2026.117995,
title = {A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC.},
author = {Liu J and Ren RQ and He Y and Zhang QH and Zhang XM and Luo XJ and Cao YZ and Wu QN and Luo HY},
year = {2026},
journal = {iScience},
doi = {10.1016/j.isci.2026.117995},
url = {https://doi.org/10.1016/j.isci.2026.117995}
}RIS
TY - JOUR TI - A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC. AU - Liu J AU - Ren RQ AU - He Y AU - Zhang QH AU - Zhang XM AU - Luo XJ AU - Cao YZ AU - Wu QN AU - Luo HY PY - 2026 JO - iScience DO - 10.1016/j.isci.2026.117995 UR - https://doi.org/10.1016/j.isci.2026.117995 ER -
APA
J, L., RQ, R., Y, H., QH, Z., XM, Z., XJ, L., YZ, C., QN, W., & HY, L. (2026). A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC.. iScience. https://doi.org/10.1016/j.isci.2026.117995
Source records
- pubmed · retrieved 2026-11-10T12:48:32.312Z